Among patients with PD-L1-high NSCLC, patients with PD after ICI therapy displayed decreased CD8 T-cell and CTL signature, increased M2 macrophages and M2 signature, and increased Tregs and Treg signature compared to patients who achieved a PR (Fig. 5e, f and Supplementary Fig. S10). This evidence concerns the gene CD8A and non-small cell lung carcinoma.